| Cancer Prevention and Control Clinical Trials Grant Program |
PAR-21-035 (R01 Clinical Trial Required) |
R01 |
Clinical Trial Required |
01/08/2024 |
Brandy Heckman-Stoddard, Ph.D., M.P.H. |
| Understanding Chronic Conditions Understudied Among Women |
RFA-OD-23-013 (R21 Clinical Trial Optional) |
R21 |
Clinical Trial Optional |
06/21/2024 |
Goli Samimi, Ph.D., M.P.H. |
| Understanding Chronic Conditions Understudied Among Women |
RFA-OD-23-014 (R01 Clinical Trial Optional) |
R01 |
Clinical Trial Optional |
06/21/2024 |
Goli Samimi, Ph.D., M.P.H. |
| Mechanisms that Impact Cancer Risk after Bariatric Surgery |
PAR-21-332 (R21 Clinical Trial Not Allowed) |
R21 |
Clinical Trial Not Allowed |
09/08/2024 |
Edward Sauter, M.D., Ph.D. |
| Mechanisms that Impact Cancer Risk after Bariatric Surgery |
PAR-21-331 (R01 Clinical Trial Optional) |
R01 |
Clinical Trial Optional |
09/08/2024 |
Edward Sauter, M.D., Ph.D. |
| NCI Clinical and Translational Exploratory/Developmental Studies |
PAR-22-216 (R21 Clinical Trial Optional) |
R21 |
Clinical Trial Optional |
07/02/2025 |
Marjorie Perloff, M.D. |
| Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics |
PAR-23-280 (R21 Clinical Trial Not Allowed) |
R21 |
Clinical Trial Not Allowed |
01/08/2027 |
Edward Sauter, M.D., Ph.D. |
| Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics |
PAR-23-279 (R01 Clinical Trial Optional) |
R01 |
Clinical Trial Optional |
01/08/2027 |
Edward Sauter, M.D., Ph.D. |